This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
post #30 is right about the mechanism and I think understates the practical bit.
Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.
I read post #32 twice before replying, because I had assumed the opposite.
Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption. The label does not establish whether the molecule is safe, efficacious, or toxic.
Compounding and pharmacy rules: some jurisdictions allow a pharmacy to compound a drug that is not on the market under specific conditions. The conditions are strict and vary by jurisdiction. Generalising from one country's rules to another's is unreliable.
Picking up post #34: that is the part I would want checked first.
Labelling and intended use: a compound sold as "research-use-only" does not change its pharmacology if ingested. It changes the legal status of the sale. The labelling tells you the intended use, not the actual use people make of it.
Coming back to post #36, because the follow-up matters more than the original answer.
Off-label use and medical practice: clinicians can prescribe approved medications off-label under some circumstances. That is different from research-use-only compounds, which are not approved for any human use.
Worth separating two things that post #36 runs together.
Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption. The label does not establish whether the molecule is safe, efficacious, or toxic.
Compounding and pharmacy rules: some jurisdictions allow a pharmacy to compound a drug that is not on the market under specific conditions. The conditions are strict and vary by jurisdiction. Generalising from one country's rules to another's is unreliable.
post #41 is right about the mechanism and I think understates the practical bit.
Import restrictions vary by compound and by jurisdiction: what is a controlled substance in one place is legal to purchase in another. What you can import for personal use depends on your country's rules, not on where it is sold.
I read post #41 twice before replying, because I had assumed the opposite.
Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.
The correction was fair and I had been repeating something I had not checked carefully enough.
Approval versus licensing: a compound can be approved for a specific indication in one country and not approved at all in another. Tracking jurisdictional approval is tedious but necessary.
On post #41 — agreed on the reasoning, with one qualification.
Regulatory positions change: a compound's status today might differ from its status a year from now. Citing a regulatory position is worth doing only with a date attached.
post #45 answers the question as asked. The question underneath it is different.
Primary documents matter: regulatory positions are published in official documents. Reading the regulatory agency's website directly is more reliable than reading a forum summary of it.
Labelling and intended use: a compound sold as "research-use-only" does not change its pharmacology if ingested. It changes the legal status of the sale. The labelling tells you the intended use, not the actual use people make of it.
Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.
Worth separating two things that post #45 runs together.
Two things before anyone answers the substance.
First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.
This follows post #48 rather than contradicting it.
Off-label use and medical practice: clinicians can prescribe approved medications off-label under some circumstances. That is different from research-use-only compounds, which are not approved for any human use.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Labelling requirements for research chemicals — the long version
Posting this under the heading it deserves: Labelling requirements for research chemicals — the long version Everything below is what sits behind that. I would like to talk about documentation quality as a…
|
2 | 1.8k | 2mo | |
|
Enforcement priorities versus written rules
Enforcement priorities versus written rules — setting out what I have, and where I think it stops being reliable. I would like to talk about documentation quality as a signal, separately from product quality.…
|
2 | 62k | 15mo | |
|
Prescription requirements and telehealth models — a second dataset
On the subject in the title: Prescription requirements and telehealth models — a second dataset Working notes rather than a conclusion. A logistics question, since the answers here are usually better than…
|
+87 | 94 | 1.1k | 21d |
|
Follow-up: How compounding permissions changed when supply normalised
How compounding permissions changed when supply normalised I have a specific reason for asking rather than idle curiosity, and the context is below. Structured report rather than an opinion, following the…
|
+72 | 77 | 1.5k | 1d |
|
Second pass at: Import rules for personal quantities, by jurisdiction, dated
Second pass at: Import rules for personal quantities, by jurisdiction, dated Writing it up because I had to work it out twice and would rather nobody else did. A logistics question, since the answers here are…
|
2 | 5k | 11mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
How to research a compound with no human data without deceiving yourself
Asking directly, because I could not find a straight answer: How to research a compound with no human data without deceiving yourself Session topic: STEP 2 ( Lancet , 2021). Please read it before posting; the…
|
+107 | 119 | 11k | 12mo |
|
Enforcement priorities versus written rules — does this still hold?
Enforcement priorities versus written rules — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Structured report rather than an opinion, following…
|
+36 | 40 | 37k | 11mo |
|
Cross-border purchase within the EU: the actual rules
Cross-border purchase within the EU: the actual rules Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is…
|
+6 | 10 | 41k | 11mo |
|
Irish differences from the UK position — what changed since
Irish differences from the UK position — what changed since — setting out what I have, and where I think it stops being reliable. Documenting an access outcome, dated, because everything in this category…
|
+8 | 12 | 782 | 1d |
|
Compounds this community declines to help with, and why — does this still hold?
Compounds this community declines to help with, and why — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SCALE ( N Engl J Med ,…
|
+3 | 7 | 26k | 7h |